Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216016 · ClinicalTrials.gov registry record · NA
Minnesota RETAIN Phase 2 (Sub-study)
A NA study of Disability and Injuries Related Work, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 5,200
- Enrollment target
- 1
- Study location
NCT05216016: Active NA study of Disability and Injuries Related Work, sponsored by Mayo Clinic.
NCT05216016 is a NA study of Disability and Injuries Related Work that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 5,200 participants, above the 477-participant average among 3 other Disability trials with a reported enrollment target (990% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216016, a NA study of Disability and Injuries Related Work, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5,200 participants
- Enrollment target
- 1
- Study location
Study Summary
MN RETAIN Phase 2 Sub-study is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant. (Effective Date: 12/23/2021-05/16/2024) MN RETAIN Phase 2 : This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant. During this Phase: additional collaborators: Mathematica Policy Research
Primary Outcome
Total number of workers employed at the time of program completion and who have maintained employment 12 months after enrollment.
Conditions Studied
Interventions
- OTHER RETAIN Program
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,200 participants |
| Start Date | 2021-12-23 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT05216016 still lists
NCT05216016 is an interventional study that assigns participants to a tested intervention. Its 5,200 participants enrollment target places it among the larger protocols in the corpus, above the 477-participant average among 3 other Disability trials with a reported enrollment target (990% higher).
The record links to 3 conditions, with Disability appearing as the primary indexed condition, and to 1 intervention - of which RETAIN Program is the first listed.
NCT05216016 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05216016 about?
NCT05216016 is a clinical study titled "Minnesota RETAIN Phase 2 (Sub-study)". MN RETAIN Phase 2 Sub-study is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Soc...
What is the current status of trial NCT05216016?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5,200 participants. The study started on 2021-12-23. Estimated completion is 2026-05.
What conditions does trial NCT05216016 study?
This clinical trial studies the following conditions: Disability, Injuries Related Work, Illness Related Work.
What interventions are being tested in trial NCT05216016?
The interventions under investigation include: RETAIN Program (OTHER).
Who is sponsoring clinical trial NCT05216016?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216016 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Disability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI